This Article Full Text Full Text (PDF) All Versions of this Article: 26/6/1236    most recent 01.ATV.0000219283.10832.43v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rip, J. Articles by Kuivenhoven, J. A. Search for Related Content PubMed PubMed Citation Articles by Rip, J. Articles by Kuivenhoven, J. A. Related Collections Lipids Lipid and lipoprotein metabolism

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:1236.)
© 2006 American Heart Association, Inc.

Brief Reviews

Lipoprotein Lipase S447X

A Naturally Occurring Gain-of-Function Mutation

Jaap Rip; Melchior C. Nierman; Colin J. Ross; Jan Wouter Jukema; Michael R. Hayden; John J.P. Kastelein; Erik S.G. Stroes; Jan Albert Kuivenhoven

From the Department of Vascular Medicine (J.R., M.C.N., J.J.P.K., E.S.G.S., J.A.K.), Academic Medical Center, University of Amsterdam, the Netherlands; Leiden University Medical Center (J.W.J.), Department of Cardiology, Leiden, The Netherlands; and the Center for Molecular Medicine and Therapeutics (C.J.R., M.R.H.), University of British Columbia, Vancouver, British Columbia, Canada

Correspondence to Jan Albert Kuivenhoven, Department of Vascular Medicine, Academic Medical Centre, University of Amsterdam (G1-113), Meibergdreef 9, 1105 AZ Amsterdam. E-mail j.a.kuivenhoven{at}amc.uva.nl

Lipoprotein lipase (LPL) hydrolyzes triglycerides in the circulation and promotes the hepatic uptake of remnant lipoproteins. Since the gene was cloned in 1989, more than 100 LPL gene mutations have been identified, the majority of which cause loss of enzymatic function. In contrast to this, the naturally occurring LPL^S447X variant is associated with increased lipolytic function and an anti-atherogenic lipid profile and can therefore be regarded as a gain-of-function mutation. This notion combined with the facts that 20% of the general population carries this prematurely truncated LPL and that it may protect against cardiovascular disease has led to extensive clinical and basic research into this frequent LPL mutant. It is only until recently that we begin to understand the molecular mechanisms that underlie the beneficial effects associated with LPL^S447X. This review summarizes the current literature on this interesting LPL variant.

It is only until recently that we begin to understand the molecular mechanisms that underlie the beneficial effects that are associated with LPL^S447X. This review summarizes the current literature on this interesting LPL variant.

Key Words: cardiovascular disease • lipids • lipoprotein lipase • lipoproteins • S447X

This article has been cited by other articles:

				S. Paglialunga, P. Julien, Y. Tahiri, F. Cadelis, J. Bergeron, D. Gaudet, and K. Cianflone Lipoprotein lipase deficiency is associated with elevated acylation stimulating protein plasma levels J. Lipid Res., June 1, 2009; 50(6): 1109 - 1119. [Abstract] [Full Text] [PDF]

				M. E. Keebler, C. L. Sanders, A. Surti, C. Guiducci, N. P. Burtt, and S. Kathiresan Association of Blood Lipids With Common DNA Sequence Variants at 19 Genetic Loci in the Multiethnic United States National Health and Nutrition Examination Survey III Circ Cardiovasc Genet, June 1, 2009; 2(3): 238 - 243. [Abstract] [Full Text] [PDF]

				K Nakayama, T Bayasgalan, K Yamanaka, M Kumada, T Gotoh, N Utsumi, Y Yanagisawa, M Okayama, E Kajii, S Ishibashi, et al. Large scale replication analysis of loci associated with lipid concentrations in a Japanese population J. Med. Genet., June 1, 2009; 46(6): 370 - 374. [Abstract] [Full Text] [PDF]

				L. Shan, X.-C. Yu, Z. Liu, Y. Hu, L. T. Sturgis, M. L. Miranda, and Q. Liu The Angiopoietin-like Proteins ANGPTL3 and ANGPTL4 Inhibit Lipoprotein Lipase Activity through Distinct Mechanisms J. Biol. Chem., January 16, 2009; 284(3): 1419 - 1424. [Abstract] [Full Text] [PDF]

				S. Kathiresan, O. Melander, D. Anevski, C. Guiducci, N. P. Burtt, C. Roos, J. N. Hirschhorn, G. Berglund, B. Hedblad, L. Groop, et al. Polymorphisms Associated with Cholesterol and Risk of Cardiovascular Events N. Engl. J. Med., March 20, 2008; 358(12): 1240 - 1249. [Abstract] [Full Text] [PDF]

				J. Wang, H. Cao, M. R. Ban, B. A. Kennedy, S. Zhu, S. Anand, S. Yusuf, R. L. Pollex, and R. A. Hegele Resequencing Genomic DNA of Patients With Severe Hypertriglyceridemia (MIM 144650) Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2450 - 2455. [Abstract] [Full Text] [PDF]

				J. D. Brown and J. Plutzky Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets Circulation, January 30, 2007; 115(4): 518 - 533. [Abstract] [Full Text] [PDF]